{"id":230055,"date":"2026-01-28T21:34:13","date_gmt":"2026-01-29T03:34:13","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/01\/patients-microdose-glp-1s-without-clinician-input"},"modified":"2026-01-28T21:34:13","modified_gmt":"2026-01-29T03:34:13","slug":"patients-microdose-glp-1s-without-clinician-input","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/01\/patients-microdose-glp-1s-without-clinician-input","title":{"rendered":"Patients Microdose GLP-1s Without Clinician Input"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/patients-microdose-glp-1s-without-clinician-input.jpg\"><\/a><\/p>\n<p>About 1 in 7 users (14.6%) of injectable GLP-1 receptor agonists (RAs) have taken or are taking them at lower doses than those approved by the FDA, and many decided to do so without clinician input, a new survey found.<\/p>\n<p>The most common reasons for GLP-1 RA microdosing are to manage tolerability, save money, and transition from weight loss to weight maintenance, according to the survey by Evidation, a California-based company that gathers healthcare information directly from members via its app.<\/p>\n<hr>\n<p>The situation was far different among respondents who were actively microdosing \u2014 only 39.8% of them said they got their medication from their current healthcare clinician. Almost 24% reported getting their GLP-1 RA from a telehealth service. Less common sources included med spas, weight-loss clinics and directly from the manufacturer.<\/p>\n<p>Telemedicine services typically offer lower-cost compounded versions of GLP-1 RAs, making them an attractive option for patients, <a href=\"https:\/\/www.medscape.com\/viewarticle\/some-patients-and-doctors-turn-microdosing-glp-1s-2025a10002y1\">noted an article<\/a> in <em>Medscape Medical News<\/em>.<\/p>\n<p>When asked about their most trusted source of information on microdosing, a larger percentage of GLP-1 RA users answered social media (26.8%) and online research (24.4%) than answered their healthcare clinician (20.3%).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>About 1 in 7 users (14.6%) of injectable GLP-1 receptor agonists (RAs) have taken or are taking them at lower doses than those approved by the FDA, and many decided to do so without clinician input, a new survey found. The most common reasons for GLP-1 RA microdosing are to manage tolerability, save money, and [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-230055","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=230055"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230055\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=230055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=230055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=230055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}